Orion Corporation: Disclosure under chapter 9, section 10 of the Securities Market Act: The total share of voting rights of Orion shares owned by Maa- ja vesitekniikan tuki ry and a company controlled by it, Tukinvest Oy, has exceeded 5%
ORION CORPORATION STOCK EXCHANGE RELEASE 28 NOVEMBER 2019 at 10.20 EET
Orion Corporation: Disclosure under chapter 9, section 10 of the Securities Market Act: The total share of voting rights of Orion shares owned by Maa- ja vesitekniikan tuki ry and a company controlled by it, Tukinvest Oy, has exceeded 5%
Orion Corporation has on 28 November 2019 received from Maa- ja vesitekniikan tuki ry a notification under Chapter 9, Section 5 of the Securities Markets Act, according to which the total share of voting rights of the Orion shares owned by Maa- ja vesitekniikan tuki ry and a company controlled by it, Tukinvest Oy, has exceeded 5% in consequence of the share conversion under the Articles of Association of Orion Corporation executed on 28 November 2019.
According to the notification, the total share of voting rights of Maa- ja vesitekniikan tuki ry and Tukinvest Oy is 5.01%.
Total positions of Maa- ja vesitekniikan tuki ry and Tukinvest Oy:
| % of voting rights (a) | % of votes through financial instruments (b) | Total of both in % (a+b) | Total number of voting rights of issuer | |
| Resulting situation on the date on which threshold was crossed or reached | 5.01% | - | 5.01% | 832,276,561 |
| Position of previous notification (if applicable) | - | - | - | - |
| % of shares (a) | % of shares through financial instruments (b) | Total of both in % (a+b) | Total number of shares of issuer | |
| Resulting situation on the date on which threshold was crossed or reached | 1.47% | - | 1.47% | 141,257,828 |
| Position of previous notification (if applicable) | - | - | - | - |
Notified details of the resulting situation on the date on which the threshold was crossed or reached::
| Class/type of shares ISIN code | Number of voting rights | % of voting rights | ||
| Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | |
| A share, FI0009014369 | 20,697,200 | 20,970,000 | 2.49% | 2.52% |
| B share, FI0009014377 | - | - | - | - |
| TOTAL | 41,667,200 | 5.01% | ||
| Class/type of shares ISIN code | Number of shares | % of shares | ||
| Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | |
| A share, FI0009014369 | 1,034,860 | 1,048,500 | 0.73% | 0.74% |
| B share, FI0009014377 | - | - | - | - |
| TOTAL | 2,083,360 | 1.47% | ||
Information in relation to person subject to the notification obligation:
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:
| Name | % of voting rights | % of voting rights through financial instruments | Total of both |
| Maa- ja vesitekniikan tuki ry | 2.49% | - | 2.49% |
| Tukinvest Oy | 2.52% | - | 2.52% |
| Name | % of shares | % of shares through financial instruments | Total of both |
| Maa- ja vesitekniikan tuki ry | 0.73% | - | 0.73% |
| Tukinvest Oy | 0.74% | - | 0.74% |
Orion Corporation
| Jari Karlson CFO | Olli Huotari SVP, Corporate Functions |
Contact person:
Tuukka Hirvonen, Investor Relations, tel. +358 010 426 2721
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion’s net sales in 2018 amounted to EUR 977 million and the company had about 3,200 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.
